IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.943
AS - Asia 9.723
EU - Europa 7.681
SA - Sud America 1.334
AF - Africa 505
Continente sconosciuto - Info sul continente non disponibili 354
OC - Oceania 14
Totale 32.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.601
SG - Singapore 3.318
CN - Cina 2.732
IT - Italia 1.807
VN - Vietnam 1.586
IE - Irlanda 1.112
FI - Finlandia 1.074
BR - Brasile 1.035
SE - Svezia 964
DE - Germania 755
HK - Hong Kong 675
UA - Ucraina 488
FR - Francia 364
ZA - Sudafrica 311
BD - Bangladesh 301
NL - Olanda 300
TR - Turchia 291
GB - Regno Unito 220
IN - India 214
CA - Canada 198
RU - Federazione Russa 168
AR - Argentina 108
AT - Austria 97
BE - Belgio 85
CI - Costa d'Avorio 75
JP - Giappone 69
MX - Messico 68
IQ - Iraq 63
ID - Indonesia 59
KR - Corea 55
PL - Polonia 55
CO - Colombia 54
PH - Filippine 49
EC - Ecuador 46
PK - Pakistan 45
ES - Italia 41
CZ - Repubblica Ceca 33
TH - Thailandia 31
VE - Venezuela 31
UZ - Uzbekistan 28
MA - Marocco 27
SA - Arabia Saudita 26
LT - Lituania 25
KE - Kenya 20
JM - Giamaica 19
IR - Iran 18
MY - Malesia 18
JO - Giordania 17
EG - Egitto 16
TN - Tunisia 15
PY - Paraguay 14
TW - Taiwan 14
AL - Albania 13
CL - Cile 13
EE - Estonia 13
UY - Uruguay 13
RO - Romania 12
AZ - Azerbaigian 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
BO - Bolivia 10
LB - Libano 10
CR - Costa Rica 9
DZ - Algeria 9
GT - Guatemala 9
HU - Ungheria 9
KZ - Kazakistan 9
NP - Nepal 9
PE - Perù 9
PS - Palestinian Territory 9
MD - Moldavia 8
GE - Georgia 7
HN - Honduras 7
IL - Israele 7
LU - Lussemburgo 7
OM - Oman 7
SY - Repubblica araba siriana 7
ET - Etiopia 6
KG - Kirghizistan 6
CH - Svizzera 5
PA - Panama 5
QA - Qatar 5
DO - Repubblica Dominicana 4
LY - Libia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PR - Porto Rico 4
TT - Trinidad e Tobago 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
BW - Botswana 3
CG - Congo 3
DK - Danimarca 3
HR - Croazia 3
LV - Lettonia 3
SI - Slovenia 3
SN - Senegal 3
SV - El Salvador 3
Totale 32.159
Salva come PNG Salva come JPEG
Città #
Singapore 1.694
Ashburn 1.395
San Jose 1.182
Dublin 1.107
Chandler 1.038
Dallas 959
Santa Clara 823
Beijing 646
Hong Kong 627
Jacksonville 564
Parma 529
Ann Arbor 508
Ho Chi Minh City 484
Council Bluffs 411
Dearborn 397
Boardman 357
Hanoi 341
Johannesburg 299
New York 275
Los Angeles 261
Nanjing 255
Izmir 234
Shanghai 232
Munich 198
Princeton 197
Lauterbourg 196
San Mateo 169
Hefei 141
Bremen 135
Milan 134
Chicago 128
Wilmington 117
Helsinki 108
São Paulo 99
Buffalo 98
Nanchang 92
Kunming 88
Toronto 88
Moscow 83
Shenyang 82
Vienna 81
Haiphong 80
Jinan 76
Abidjan 75
Hebei 74
Woodbridge 69
Bologna 68
Des Moines 68
Brussels 67
Da Nang 61
Rome 58
Marseille 57
Frankfurt am Main 56
Modena 56
Tianjin 56
Houston 52
Seattle 51
Columbus 49
Phoenix 49
The Dalles 49
Pune 47
Turku 46
Tokyo 45
Brooklyn 44
Guangzhou 44
Jiaxing 42
Warsaw 42
Amsterdam 41
Changsha 41
London 40
Washington 40
Rio de Janeiro 38
Denver 36
Stockholm 35
Jakarta 34
Montreal 34
Düsseldorf 30
Reggio Emilia 30
Seoul 30
Hangzhou 28
San Francisco 28
Atlanta 27
Biên Hòa 27
Dhaka 27
Orem 27
Tashkent 27
Norwalk 26
Manchester 25
Belo Horizonte 24
Brasília 24
Redmond 24
Boston 23
Hải Dương 23
Levanto 23
Chennai 22
Leawood 22
Nuremberg 22
Campinas 21
Curitiba 21
Baghdad 20
Totale 19.273
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 367
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 314
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 296
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 267
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 267
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 263
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 235
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 233
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 225
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 224
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 223
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 223
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 222
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 221
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 221
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 221
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 220
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 217
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 215
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 214
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 213
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 210
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 209
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 207
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 207
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 205
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 203
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 201
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 199
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 199
Characterization of gefitinib uptake in NSCLC cell lines 197
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 197
Antitumoral effect of a nanotechnology-based photodynamic therapy. 197
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 194
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 193
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 191
5-benzylidene-hydantoins as new inhibitors of cell proliferation 190
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 190
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 189
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 189
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 188
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 188
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 187
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 186
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 186
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 184
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 183
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 182
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 179
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 179
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 178
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 177
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 176
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 175
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 174
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 173
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 173
An original application of plasma expanders: heart-lung preservation. 173
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 171
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 170
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 170
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 169
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 169
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 167
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 165
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 165
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 164
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 164
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 163
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 163
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 160
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 160
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 160
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 159
Synergistic activity of letrozole and sorafenib on breast cancer cells 157
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 155
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 155
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 155
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 154
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 154
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 153
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 153
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 153
New MDR1 inhibitors for overcoming multidrug resistance 153
SiO2/SiC core-shell nanowires for nanomedicine applications 153
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 152
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 151
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 151
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 151
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 151
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 151
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 150
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 150
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 149
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 149
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 148
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 148
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 148
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 148
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 147
Totale 18.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022893 0 0 0 65 34 14 135 119 60 71 67 328
2022/20234.206 399 434 276 278 414 466 44 297 1.364 25 169 40
2023/20241.762 86 139 60 64 157 403 129 131 68 88 155 282
2024/20255.391 177 281 345 406 496 566 305 223 737 463 472 920
2025/202611.663 1.026 1.078 1.418 1.061 1.562 659 1.286 362 1.625 864 457 265
2026/20272.152 372 613 621 546 0 0 0 0 0 0 0 0
Totale 32.554